Cooperative Agreement U01CA294551
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$1.1M
Federal Agency
National Cancer Institute
Federal Grant Program
93.353
Assistance Type
Cooperative Agreement
Place of Performance
Pasadena, CA 91125, USA
Similar Awards
This federal Cooperative Agreement award, provided by the National Cancer Institute (CFDA 93.353 - 21st Century Cures Act - Beau Biden Cancer Moonshot), is intended to establish a comprehensive Pediatric Solid Tumor Microenvironment (PSTME) Atlas. The $1,149,870 award, with a project period from Sep 1, 2024 to Aug 31, 2029, will support a collaborative effort between Children's Hospital Los Angeles (CHLA) and the California Institute of Technology (Caltech) to investigate the spatial biology...
This Project Grant award of $249,000 from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research by the University of Pennsylvania to provide fundamental insights into the evolution and progression of glioma, an incurable brain cancer. The research aims to develop a multi-dimensional model of glioma progression by using novel single-cell technologies to concurrently profile the transcriptome, epigenome, and genome of glioma cells. This will help define...
This Cooperative Agreement award, titled "AN ATLAS OF PANCREATIC TUMORIGENESIS IN THE CONTEXT OF ALTERED DNA REPAIR OCCURRING IN HIGH-RISK INDIVIDUALS", is funded by the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353). The $1,035,138 award, effective September 1, 2024 through August 31, 2029, will support the creation of a comprehensive molecular and cellular 3D atlas depicting the progression of pancreatic...
The U.S. National Cancer Institute (NCI) awarded a $1,069,873 Cooperative Agreement under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) to The University of Texas MD Anderson Cancer Center to establish the Center for Gastric Pre-Cancer Atlas of Multidimensional Evolution in 3D (GAME3D). This 5-year project aims to develop a multimodal, single-cell, dynamic, and 3D spatial atlas of normal-appearing gastric mucosa, precancerous T1A lesions, and advanced diffuse...
This $1,018,682 Cooperative Agreement award from the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) supports the construction of a spatiotemporal atlas of human follicular lymphoma (FL) transformation to diffuse large B-cell lymphoma (DLBCL) and angioimmunoblastic T-cell lymphoma (AITL) evolution. The Yale University-led Center for Human Lymphoma Spatiotemporal Atlas (HULYMSTA) project will leverage single-cell and spatial...
The National Cancer Institute awarded a $423,078 Project Grant (CFDA Program 93.394 - Cancer Detection and Diagnosis Research) to the California Institute of Technology (Caltech) to develop a machine learning framework that uses spatial proteomic data to identify signaling molecules and guidance cues that can promote T-cell infiltration and function in "cold" tumors. The project aims to generalize this approach across a broader range of cancer types and larger patient data sets, and...
The National Cancer Institute (NCI) awarded a 5-year, $1,019,013 cooperative agreement under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) to The Regents of the University of California, San Francisco (UCSF) to develop a Pre-Cancer Atlas of Skin Cancer. The goal is to understand the early stages of tumor development and the role of the immune system in shaping skin cancer evolution, focusing on melanoma and cutaneous squamous cell carcinoma. The research will...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) is focused on understanding the metabolic mechanisms driving glioma progression, one of the most lethal and treatment-resistant forms of brain cancer. The $682,596 award will fund research conducted by The University of Texas Southwestern Medical Center to uncover how metabolic reprogramming and aberrant metabolite secretion by glioma cells impacts neuron excitability and tumor growth....
The National Cancer Institute (NCI) has awarded a 5-year, $639,642 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the University of Wisconsin - Madison to develop an advanced "Radiomic Spatial Map" (RAD-I Map) technology for non-invasively identifying the full extent of glioblastoma (GBM) tumors.
The project aims to enhance the initial RAD-I Map by incorporating additional MRI sequences and a novel "lesion complexity" feature to more accurately...
This federal Project Grant award from the U.S. Department of Health and Human Services' National Cancer Institute provides $547,519 to Oregon Health & Science University (OHSU) to leverage biologically-specific PET/MRI monitoring and therapeutic modulation of the hypoxic glioblastoma tumor immune microenvironment (TIME) in order to improve outcomes for patients with glioblastoma, an aggressive form of brain cancer.
The key objectives are to: 1) Define a biologically-specific imaging...